The Office of Research Administration (ORA) is a vital Shared Resource of the Cancer Therapy and Research Center (CTRC) at The University of Texas Health Science Center at San Antonio (UTHSCSA; termed CTRC). The ORA allows centralizafion of protocol and data management funcfions, a crifical need for CTRC's successful operafion due both to the increasingly complex nature of clinical research and the need to ensure opfimal integration with UTHSCSA ethics and regulatory bodies. In order to ensure the highest level of patient safety and research quality, the ORA supports both the Data Safety and Monitoring Committee (DSMC) and Protocol Review Committee (PRC). The DSMC is charged with the responsibility for monitoring, reviewing, and taking administrafive acfion as needed on all active CTRC studies. All studies are monitored unfil every patient has completed treatment and follow-up on study. The DSMC oversees all aspects of research data validity and integrity, ensures regulatory compliance, and protects the safety of participants in all CTRC clinical studies. The PRC function is to review, prior to UTHSCSA Institufional Review Board (IRB) submission, all clinical CTRC studies for scientific merit and to ensure appropriate prioritizafion in terms of accrual and Shared Resource ufilizafion. The ORA provides centralized support for all CTRC invesfigators including, but not limited to, protocol development, centralized data collecfion and disseminafion of protocol information with supporting documents, registration of pafients onto approved clinical trials following confirmafion of pafient eligibility, and assistance in data analysis. The ORA serves as an interface with the IRB to facilitate preparation of the required consent and HIPAA forms, and other regulatory documents necessary to expedite effective review and opening of cancer center protocols. The ORA is comprised of five divisions: Regulatory Affairs, Contracts and Budgets, Clinical Invesfigations, Pafient Referral, and Quality Assurance. These groups are highly integrated to ensure compliance, standardization, institufion-wide involvement in quality assurance processes, accurate and rapid patient enrollment, fiscal responsibility, and a funcfional collegial non-duplicative interface with the relevant UTHSCSA bodies. The ORA works closely with the Biostafisfics and Informafics Shared Resource which is responsible for the design, implementafion and maintenance of the Informatics Data Exchange and Acquisifion System (IDEAS) database. DEAS is used to monitor data quality metrics, protocol compliance, enrollment rates, to identify data entry issues, to and to generate queries. ORA acfivifies have resulted in a consistenfiy high level of accrual to clinical trials during this grant period with excellent reports on numerous audits from sponsors and the NCI. The ORA Director reports to Dr. Giles, the CTRC Deputy Director.

Public Health Relevance

The ORA's relevance to CTRC research is its pivotal role in ensuring the highest levels possible of both patient safety and quality of research conducted in the cancer center. The ORA is vital to the submission and implementation of research studies associated with P30 programs. By providing these centralized services, investigators are able to concentrate on research conduct and patient care which, when combined with ORA and support, allows both to be optimal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA054174-18
Application #
8107452
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
18
Fiscal Year
2010
Total Cost
$26,039
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :
Arora, Sukeshi Patel; Mahalingam, Devalingam (2018) Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 9:170-179
Arellano, Luisa M; Arora, Sukeshi Patel (2018) Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. J Nat Sci 4:

Showing the most recent 10 out of 989 publications